Kintara Therapeutics Provides Update On REM-001 Clinical Study, Has Enrolled 4 Of The 10 Patients Needed To Reach The Minimum Patient Enrollment To Assess Safety And Appropriate Phase 3 Dose With Several Other Patients Identified As Study Candidates At Kintara's Clinical Sites, No Treatment-Related Safety Issues Have Been Identified To-Date, And Assessment Of The Appropriate Phase 3 Dose Is Ongoing
Portfolio Pulse from Benzinga Newsdesk
Kintara Therapeutics has enrolled 4 out of 10 patients in its REM-001 clinical study for cutaneous metastatic breast cancer, with no safety issues reported. The study is funded by a $2 million NIH grant, but Kintara may face financial challenges without a merger with TuHURA.
September 11, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kintara Therapeutics' REM-001 study is progressing with 4 of 10 patients enrolled and no safety issues. The study is funded by a $2M NIH grant, but financial stability is uncertain without a merger with TuHURA.
The enrollment progress and absence of safety issues are positive, but the company's financial future is uncertain without the merger, which could impact stock stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100